Participant in MS Trial Dies After Receiving New Therapy
A patient in a multiple sclerosis clinical study died 44 days after receiving a CAR T-cell treatment.
Updated on Oct. 24, 2026 in Stroke
A study participant recently died of septic pneumonia 44 days after receiving an investigational CAR T-cell therapy, zolacabtagene autoleucel, for multiple sclerosis. This event occurred within a Phase 1 study cohort of 66 patients.
Why it matters
Understanding safety profiles in early-stage trials is vital for patients monitoring the progress of new immunotherapy options for multiple sclerosis. This report highlights the complex side effects associated with CAR T-cell interventions in autoimmune research.
In a Phase 1 study of 66 patients with multiple sclerosis, one participant died of septic pneumonia 44 days after receiving the investigational CAR T-cell therapy zolacabtagene autoleucel. No other Grade 5 events have been reported among the 190 patients treated across all autoimmune disease programs.
The players
Bristol Myers Squibb
A global biopharmaceutical company developing immunotherapies, including CAR T-cell treatments for cancer and autoimmune conditions.
The details
Zolacabtagene autoleucel is an investigational CAR T-cell therapy designed to target immune cells involved in disease progression. Patients in the study faced notable immune side effects, including cytokine release syndrome, which affected 28 individuals, and immune effector cell-associated neurotoxicity syndrome, which occurred in five patients. The deceased participant had also received high-dose cyclophosphamide one day before death and had been treated with corticosteroids and immunoglobulin for persistent motor symptoms.
Timeline
44 days after receiving the therapy, the study participant died.
One day before the death occurred, the patient received high-dose cyclophosphamide.
Health Landscape
This development occurs within Bristol Myers Squibb's broader effort to determine the safety and efficacy of CAR T-cell therapies for autoimmune conditions. It marks a significant safety event in a field currently balancing the potential for disease modification against severe immune-mediated risks.
Patients tracking clinical trial developments for multiple sclerosis should note that these treatments remain in early-phase investigation and carry significant, distinct immune risks. Any concerns regarding current treatment protocols or new therapy eligibility are best addressed through a conversation with a neurologist.
The takeaway
This case underscores the clinical intensity of CAR T-cell trials and the necessity of rigorous safety monitoring for patients with progressive or highly active disease. Keep updated on trial outcomes by consulting your neurologist to understand how evolving research might eventually impact standard treatment options.
Further reading
For more on managing autoimmune health and related neurological symptoms, visit the Stroke section.
Source note: This article includes information reported by TokenPost.
